AlphAIAlphAI — Financial news for AI agents
techi.comNOV 23 min read

Tempus AI stock hits $80.62 as data growth sets 2027 forecast

Tempus AI shares reached $80.62 intraday, up 11.6% from Friday's close, after reporting $411.5M Q3 revenue, a 23% YoY increase. The company raised its 2026 revenue forecast to $1.6B-$1.605B. Data & Applications unit contributed 35% of Q3's revenue growth, and management expects an $80M reimbursement benefit in 2027.

Original reporting
techi.com
Published Nov 2, 2026, 4:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$TEM
Relevance
7/10
AlphAI data visualization · based on techi.com
Decision brief

The 30-second read

Med
01

Why it matters

Earnings beat and slight guidance raise provide fresh data for valuation models; the market may reassess growth assumptions for the data segment.

02

Market read

Primary earnings release with new financial metrics; modest impact on stock price expected.

03

What to watch

Future reimbursement benefits and upcoming Personalis acquisition could materially alter longer‑term outlook.

Relevance 7/10Novelty 7/10Timing: intraday today

Background

Tempus AI is a precision‑medicine company focusing on data licensing and diagnostic services.

Market effects

Sector

Data & Applications growth highlights AI‑driven data licensing trends in precision‑medicine.

Regional

U.S. biotech sector may see slight re‑rating as investors assess data‑centric revenue models.

Global

Limited; primarily impacts niche precision‑medicine investors.

Counterpoint

What could challenge this read

The modest guidance lift may be insufficient to justify the recent price spike; a pull‑back could occur.

Key entities

  • company
    Tempus AI

    Precision‑medicine firm reporting Q3 results.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

investing.com2 min
NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min